Sage Therapeutics

Developer of drug candidates for the treatment of rare CNS disorders

placeBoston, Massachusetts, United States calendar_todayFounded 1971 groups487 employees language sagerx.com

Innovation

127 patent families (53 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 32,092 times.

YearFilings
201515
201621
201732
201837
201950
202051
202164
202261
202379
202479
202565
202623

Social engagement

Social engagement: 114.5K social following, 1 post in the last 12 months — below the industry typical range.

Investor mix

13 investors on record; lead investors include Orbimed, Foresite Capital, EcoR1.

Investor typeCountShare
Venture capital538%
Private equity323%
Other / undisclosed538%

Recent activity

13 Feb 2026
Partnership
Sage Therapeutics
Coming soon